| Baseline characteristics . | PFA (N = 161) . | PowerPlus (N = 161) . | P-value . |
|---|---|---|---|
| Woman, n (%) | 58 (36) | 60 (37) | 0.8 |
| Age, median (IQR), years | 65 (59; 71) | 65 (59; 72) | 0.9 |
| Hypertension, n (%) | 80 (50) | 77 (48) | 0.7 |
| SHD, n (%) | 27 (17) | 28 (17) | 0.9 |
| Diabetes, n (%) | 14 (9) | 15 (9) | 0.9 |
| Normal LVEF, n (%) | 151 (94) | 146 (91) | 0.3 |
| BMI, median (IQR), kg/m2 | 26 (25; 30) | 27 (25; 29) | 0.7 |
| LA diameter (parasternal long axis), median (IQR), mm | 41 (36; 44) | 40 (36; 43) | 0.2 |
| CHA2DS2VASC | 2 (1; 3) | 2 (1; 3) | 0.7 |
| Paroxysmal AF, n (%) | 125 (78) | 123 (76) | 0.8 |
| Persistent AF, n (%) | 36 (22) | 38 (24) | 0.6 |
| Diagnosis to ablation time, median (IQR), months | 12 (4; 36) | 12 (4; 36) | 0.7 |
| OAC before the procedure | 150 (93) | 133 (83) | 0.01 |
| AAD before the procedure | 103 (64) | 87 (54) | 0.07 |
| Baseline characteristics . | PFA (N = 161) . | PowerPlus (N = 161) . | P-value . |
|---|---|---|---|
| Woman, n (%) | 58 (36) | 60 (37) | 0.8 |
| Age, median (IQR), years | 65 (59; 71) | 65 (59; 72) | 0.9 |
| Hypertension, n (%) | 80 (50) | 77 (48) | 0.7 |
| SHD, n (%) | 27 (17) | 28 (17) | 0.9 |
| Diabetes, n (%) | 14 (9) | 15 (9) | 0.9 |
| Normal LVEF, n (%) | 151 (94) | 146 (91) | 0.3 |
| BMI, median (IQR), kg/m2 | 26 (25; 30) | 27 (25; 29) | 0.7 |
| LA diameter (parasternal long axis), median (IQR), mm | 41 (36; 44) | 40 (36; 43) | 0.2 |
| CHA2DS2VASC | 2 (1; 3) | 2 (1; 3) | 0.7 |
| Paroxysmal AF, n (%) | 125 (78) | 123 (76) | 0.8 |
| Persistent AF, n (%) | 36 (22) | 38 (24) | 0.6 |
| Diagnosis to ablation time, median (IQR), months | 12 (4; 36) | 12 (4; 36) | 0.7 |
| OAC before the procedure | 150 (93) | 133 (83) | 0.01 |
| AAD before the procedure | 103 (64) | 87 (54) | 0.07 |
SHD, structural heart disease; LVEF, left ventricular ejection fraction; BMI, body mass index; LA, left atrium; OAC, oral anticoagulation; AAD, anti-arrhythmic drug; IQR, inter-quartile range.
| Baseline characteristics . | PFA (N = 161) . | PowerPlus (N = 161) . | P-value . |
|---|---|---|---|
| Woman, n (%) | 58 (36) | 60 (37) | 0.8 |
| Age, median (IQR), years | 65 (59; 71) | 65 (59; 72) | 0.9 |
| Hypertension, n (%) | 80 (50) | 77 (48) | 0.7 |
| SHD, n (%) | 27 (17) | 28 (17) | 0.9 |
| Diabetes, n (%) | 14 (9) | 15 (9) | 0.9 |
| Normal LVEF, n (%) | 151 (94) | 146 (91) | 0.3 |
| BMI, median (IQR), kg/m2 | 26 (25; 30) | 27 (25; 29) | 0.7 |
| LA diameter (parasternal long axis), median (IQR), mm | 41 (36; 44) | 40 (36; 43) | 0.2 |
| CHA2DS2VASC | 2 (1; 3) | 2 (1; 3) | 0.7 |
| Paroxysmal AF, n (%) | 125 (78) | 123 (76) | 0.8 |
| Persistent AF, n (%) | 36 (22) | 38 (24) | 0.6 |
| Diagnosis to ablation time, median (IQR), months | 12 (4; 36) | 12 (4; 36) | 0.7 |
| OAC before the procedure | 150 (93) | 133 (83) | 0.01 |
| AAD before the procedure | 103 (64) | 87 (54) | 0.07 |
| Baseline characteristics . | PFA (N = 161) . | PowerPlus (N = 161) . | P-value . |
|---|---|---|---|
| Woman, n (%) | 58 (36) | 60 (37) | 0.8 |
| Age, median (IQR), years | 65 (59; 71) | 65 (59; 72) | 0.9 |
| Hypertension, n (%) | 80 (50) | 77 (48) | 0.7 |
| SHD, n (%) | 27 (17) | 28 (17) | 0.9 |
| Diabetes, n (%) | 14 (9) | 15 (9) | 0.9 |
| Normal LVEF, n (%) | 151 (94) | 146 (91) | 0.3 |
| BMI, median (IQR), kg/m2 | 26 (25; 30) | 27 (25; 29) | 0.7 |
| LA diameter (parasternal long axis), median (IQR), mm | 41 (36; 44) | 40 (36; 43) | 0.2 |
| CHA2DS2VASC | 2 (1; 3) | 2 (1; 3) | 0.7 |
| Paroxysmal AF, n (%) | 125 (78) | 123 (76) | 0.8 |
| Persistent AF, n (%) | 36 (22) | 38 (24) | 0.6 |
| Diagnosis to ablation time, median (IQR), months | 12 (4; 36) | 12 (4; 36) | 0.7 |
| OAC before the procedure | 150 (93) | 133 (83) | 0.01 |
| AAD before the procedure | 103 (64) | 87 (54) | 0.07 |
SHD, structural heart disease; LVEF, left ventricular ejection fraction; BMI, body mass index; LA, left atrium; OAC, oral anticoagulation; AAD, anti-arrhythmic drug; IQR, inter-quartile range.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
